Back to News
Market Impact: 0.4
Ionis Pharmaceuticals Announces FDA Approval of HIBSAGO, Eligible for 10-12% Royalties
Source: Nasdaq
Healthcare & BiotechProduct Launches
Ionis Pharmaceuticals said its partner GSK announced FDA approval of HIBSAGO for chronic hepatitis B virus infection, in combination with nucleos(t)ide analogue reverse transcriptase inhibitor therapy. The article text is truncated, so further details about the approved population, commercial outlook, or market reaction are unavailable.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
GSK0.70
IONS0.50
More News
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Palmer Luckey teams with dire wolf billionaire Ben Lamm to launch $200 million Warhound, unleashing genetically engineered clone dogs of war
- Meta Platforms beat the Street. Here's why analysts are bullish on the stock